5 Best Income Stocks To Invest In 2014

As interest rates wallow at historic lows, many investors have been flocking to dividend stocks. Even massive blue-chip companies like Johnson & Johnson (NYSE: JNJ  ) have significantly outpaced the broader market as yield-hungry investors have bid up prices.�

One sector that has been largely ignored by income-focused investors is the financial sector. With prices still depressed since the onset of the financial crisis, Wells Fargo (NYSE: WFC  ) is yielding over 3%, and JPMorgan Chase (NYSE: JPM  ) boasts a 2.9% annual dividend yield. In this video, Motley Fool banking analyst David Hanson tells investors why these two banks may be a safer bet than other stocks known for their dividends, as well as two other banks that could become solid dividend payers.

5 Best Defensive Stocks For 2015: Austin Engineering Ltd (ANG)

Austin Engineering Limited is engaged in the manufacture, repair, overhaul and supply of mining attachment products, general steelwork structures and other associated products and services for the industrial and resources-related business sectors. The Company operates in four segments: Australia, which includes mining equipment, other products and repair and maintenance services; Americas, which includes mining equipment and other products, consisting of North America and South America; Asia, which includes Indonesia for mining equipment and other products, and the Middle East, which includes aluminum smelter equipment and products. In October 2013, Austin Engineering Limited completed the acquisition of the business of Servigrut. Advisors' Opinion:

• [By Julia Leite]

  South African miners rallied after a recovery in gold prices. The FTSE/JSE Africa All-Share Index climbed 1.5 percent in Johannesburg, with Harmony Gold Mining Co. (HAR) and AngloGold Ashanti Ltd. (ANG) adding at least 5.2 percent.

5 Best Income Stocks To Invest In 2014: Transcananda Pipelines Ltd.(TRP)

Transcanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Oil Pipelines, and Energy. The Natural Gas Pipelines segment develops and operates energy infrastructure, including natural gas pipelines and regulated gas storage facilities. Its network of natural gas pipelines extends approximately 60,000 km tapping into gas supply basins in North America. The Oil Pipelines segment operates Keystone crude oil pipeline system, which includes completed 3,467 km Wood River/Patoka and Cushing Extension phases, and the proposed 2,673 km U.S. Gulf Coast Expansion. The Energy segment engages in the acquisition, development, construction, ownership, and operation of electrical power generation plants; the purchase and marketing of electricity; the provision of electricity account services to energy and industrial customers; and the development, construction, ownership, and operation of non-regulat ed natural gas storage in Alberta. The company was founded in 1951 and is headquartered in Calgary, Canada.

Advisors' Opinion:

• [By Arjun Sreekumar]

  Light at the end of the tunnel?
  One major lifesaver for Canadian oil sands projects might be the proposed Keystone XL pipeline, operated by Canadian midstream operator TransCanada (NYSE: TRP  ) . The pipeline would transport hundreds of thousands of barrels from Alberta to major U.S. hubs and has been cited by several analysts as the major catalyst that could help narrow the price gap between Western Canadian crude and other North American crude oil benchmarks.

• [By Isac Simon]

  President Obama's climate change address at Georgetown University has been hailed as among his best by environmental activists. However, the president's much awaited response to TransCanada's (NYSE: TRP  ) Keystone XL pipeline, hasn't exactly been the best in terms of clarity.

• [By Benjamin Shepherd]

  TransCanada (TRP) has increased its dividend as reliably as Kimberly Clark, sustaining a yield of about 4% and generating a total return of 58% over the past five years.

5 Best Income Stocks To Invest In 2014: Hospira Inc (HSP)

Hospira, Inc. (Hospira), incorporated on September 16, 2003, is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira's portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products.

Specialty Injectable Pharmaceuticals

Hospira's specialty injectable pharmaceutical products consist of generic injectable pharmaceuticals. The other drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. All of Hospira's generic injectable pharmaceuticals in the United States include unit-of-use bar-code labels that can be used to support medication delivery. Hospira primarily procures the active pharmaceutical ingredients in these products from third-party suppliers. During the year ended December 31, 2011, Hospira portfolio included 87 injectable drug launches consisting of 13 compounds. Among these launches included, in the United States, docetaxel (an oncolytic drug used to treat a variety of cancers), topotecan (an oncolytic drug used for the treatment of small cell lung cancer) and imipenem-cilastatin (a beta-lactam antibiotic). Hospira also launched a solution formulation of gemcitabine (an oncolytic drug used to treat a variety of cancers), which augmented Hospira's portfolio of gemcitabin! e products. New-to-country launches in EMEA in 2011, included topotecan, meropenem, gemcitabine, imipenem-cilastatin, remifentanil, docetaxel and levofloxacin. New-to-country launches in APAC in 2011, included docetaxel, piperacillin tazobactam, oxaliplatin, meropenem and gemcitabine. Hospira's specialty injectable pharmaceutical products also include Precedex (dexmedetomidine HCl), a sedative. Precedex is licensed to Hospira by Orion Corporation in the Americas and APAC segments, and in the Middle East and Africa.

Hospira sells and markets Precedex for use in non-intubated patients requiring sedation, as well as intubated and mechanically ventilated patients. Hospira's specialty injectable pharmaceuticals also include biologic products, which are molecules derived from cells that are demonstrated to be similar to an approved originator product. Hospira's biosimilar, Retacrit, was available in 20 EMEA countries during 2011. Its second biosimilar, Nivestim, was launched during the year ended December 31, 2010, and was available in 21 countries, including Australia, where the biosimilar filgrastim product was launched in 2011. Hospira's drug delivery formats include offerings in ampules and flip-top vials, which clinicians can use with standard syringes. Hospira's drug delivery options include Carpuject and iSecure prefilled syringes, AnsyrTM prefilled needleless emergency syringe systems, First Choice ready-to-use premix and the ADD-Vantage system for preparing drug solutions from prepackaged drug powders or concentrates.

Other Pharmaceuticals

Hospira's other pharmaceuticals primarily consist of intravenous (I.V.) solutions, nutritionals and contract manufacturing services. Hospira offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. All of Hospira's injectable I.V. solutions in the United States include unit-of-use bar-c! ode label! s that can be used to support medication management efforts. Hospira also offers infusion therapy solutions in its VisIV non-PVC, non-DEHP I.V. container, an I.V. bag. Hospira's contract manufacturing services are offered through its One2One services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. Hospira works with its pharmaceutical and biotechnology customers to develop injectable forms of their drugs, and Hospira fills and finishes those and other drugs into containers and packaging selected by the customer. The customer then sells the finished products under its own label. Hospira's One2One manufacturing services group generally does not manufacture active pharmaceutical ingredients, but offers a range of filling and finishing services in a variety of delivery systems.

Medication Management

Medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to Hospira pumps. These sets are used to deliver I.V. fluids and medications. Hospira also offers software maintenance agreements and other service offerings. Hospira's electronic drug delivery pumps include Hospira's general infusion system, Symbiq; the Plum A+ line of infusion pumps; Hospira's patient-controlled analgesia device, LifeCare PCA; the GemStar ambulatory infusion pump; and the Plum XLD infusion pump. Hospira offers the Hospira MedNet safety software system, which has been designed to enable hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. The Hospira MedNet system is standard in the Symbiq infusion system, and is also available as an additional feature for the Plum A+ line, and LifeCare PCA devices. Hospira also offers safety software with its Ge! mStar pum! p.

Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers' needlestick prevention initiatives. LifeShield CLAVE and LifeShield MicroCLAVE connectors are one-piece valves that directly connect syringes filled with medications to a patient's I.V. line without the use of needles. ICU Medical's CLAVE connectors are a component of administration sets sold by Hospira to its customers in the United States and select markets outside the United States.

The Company competes with Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi, Pfizer, Sandoz, Sanofi, Teva Pharmaceuticals, B. Braun Melsungen AG, CareFusion, Terumo, Actavis, Intas Pharmaceuticals, Ltd, Medac GmbH, Mylan Inc., Sun Pharmaceutical Industries, Ltd. and Aspen.

Advisors' Opinion:

• [By Ben Levisohn]

  That decision has helped make Allergan the top performing pharmaceutical stock in the S&P 500. Its shares have gained 4.3% to $108.18, today at 2:32 p.m., besting Merck’s (MRK) 1.2% rise to $49.36, Mylan’s (MYL) 1.1% advance to $42.98, Hospira’s (HSP) 0.7% increase to $41.34 and Eli Lily’s (LLY) 0.6% rise to $50.42.

• [By Holly LaFon]

  Company % of Assets Pepsico (PEP) 3.4 Philip Morris (PM) 2.3 Tesco PLC ADR (TSCO) 2.1 Molson Coors Brewing (TAP) 2.1 Microsoft (MSFT) 1.9 Merck (MRK) 1.9 Procter & Gamble (PG) 1.8 Avon Products (AVN) 1.6 Wal��art (WMT) 1.6 Medtronic 1.6 Hospira (HSP) 1.5 BP (BP) 1.4 Medco Health Solutions (MHS) 1.3 Johnson & Johnson (JNJ) 1.3 Unilever NV (UL) 1.3
  Jeff is also optimistic about natural gas and believes the recession in Europe could be setting up "a generational buying opportunity."

• [By Dimitra DeFotis]

  Walgreen (WAG) stock is down 2.4%, despite speculation today that hospital products company�Hospira�(HSP) could bid for Danone�� medical-nutrition unit in what would be the latest so-called inversion deal — and a big one at possibly $5.1 billion. �Already in the works:�AbbVie�(ABBV) and�Medtronic�(MDT) are pursuing deals with�smaller Irish rivals that will permit the companies to switch their home base to Ireland.

• [By Alyssa Oursler]

  On top of that, Cubist won an important legal battle earlier this year against Hospira (HSP), a company that was planning a generic-drug challenge against what is currently Cubist’s leading treatment. That’s a big win considering the generic market has been eating countless name-brand drug-makers’ lunch.

5 Best Income Stocks To Invest In 2014: Domtar Corp (UFS)

Domtar Corporation, incorporated on August 16, 2006, designs, manufactures, markets and distributes a range of fiber-based products, including communication papers, specialty and packaging papers and adult incontinence products. The Company operates in three business segments: Pulp and Paper, Distribution and Personal Care. Its Pulp and Paper segment consists of the manufacturing, sale and distribution of communication, specialty and packaging papers, as well as softwood, fluff and hardwood market pulp. The Company�� Distribution segment includes the purchasing, warehousing, sale and distribution of its paper products and those of other manufacturers. These products include business and printing papers, certain industrial products and printing supplies. Its Personal Care segment consists of the manufacturing, sale and distribution of adult incontinence products.The Company is an integrated marketer and manufacturer of uncoated freesheet paper in North America for a variety of customers, including merchants, retail outlets, stationers, printers, publishers, converters and end-users. The Company produces incontinence care products marketed primarily under the Attends brand. The Company owns and operates Ariva. On May 10, 2012, the Company acquired EAM Corporation. In June 2013, the Company announced the completion of its acquisition of Xerox Corp paper and print media products business in the United States and Canada. In July 2013, Domtar Corp announced that completion of the acquisition of Associated Hygienic Products (AHP) from DSG International. In January 2014, the Company acquired Laboratorios Indas, SAU.

Pulp and Paper

The Company produces 4.2 million metric tons of hardwood, softwood and fluff pulp at 12 of its 13 mills. The majority of its pulp is consumed internally to manufacture paper and consumer products, with the balance being sold as market pulp. The Company also purchases papergrade pulp from third parties. The Company has 10 pulp and paper mills (eight in the! United States and two in Canada), with an annual paper production capacity of approximately 3.4 million tons of uncoated freesheet paper. Its paper manufacturing operations are supported by 15 converting and distribution operations, including a network of 12 plants located offsite of its paper making operations. In addition, it has forms manufacturing operations at three offsite converting and distribution operations. Approximately 81% of its paper production capacity is in the United States, and the remaining 19% is located in Canada.

The Company produces market pulp in excess of its internal requirements at its three non-integrated pulp mills in Kamloops, Dryden, and Plymouth, as well as at its pulp and paper mills in Espanola, Ashdown, Hawesville, Windsor, Marlboro and Nekoosa. The Company sells approximately 1.6 million metric tons of pulp per year depending on market conditions. Approximately 50% of its trade pulp production capacity is in the United States, and the remaining 50% is located in Canada. The fiber used by its pulp and paper mills in the United States is hardwood and softwood, both being readily available in the market from multiple third-party sources. The fiber used at its Windsor pulp and paper mill is hardwood originating from a variety of sources, including purchases on the open market in Canada and the United States, contracts with Quebec wood producers��marketing boards, public land where it has wood supply allocations and from its private lands. The softwood and hardwood fiber for its Espanola pulp and paper mill and the softwood fiber for its Dryden pulp mill, is obtained from third parties, directly or indirectly from public lands, through designated wood supply allocations for the pulp mills. The fiber used at the Company�� Kamloops pulp mill is all softwood, originating from third-party sawmilling operations in the southern-interior part of British Columbia.

The Company uses various chemical compounds in its pulp and paper manufacturing facili! ties that! it purchases, primarily on a central basis, through contracts. For pulp manufacturing, it uses numerous chemicals, including caustic soda, sodium chlorate, sulfuric acid, lime and peroxide. For paper manufacturing, it also uses several chemical products, including starch, precipitated calcium carbonate, optical brighteners, dyes and aluminum sulfate. It owns power generating assets, including steam turbines, at all of its integrated pulp and paper mills, as well as hydro assets at four locations: Espanola, Ottawa-Hull, Nekoosa and Rothschild. The Company�� business papers include copy and electronic imaging papers, which are used with ink jet and laser printers, photocopiers and plain-paper fax machines, as well as computer papers, preprinted forms and digital papers. These products are primarily for office and home use. The Company�� commercial printing and publishing papers include uncoated freesheet papers, such as offset papers and opaques. These uncoated freesheet grades are used in sheet and roll fed offset presses across the spectrum of commercial printing end-uses, including digital printing. Its publishing papers include tradebook and lightweight uncoated papers used primarily in book publishing applications, such as textbooks, dictionaries, catalogs, magazines, hard cover novels and financial documents. Design papers, a sub-group of commercial printing and publishing papers, have features of color, brightness and texture and are targeted towards graphic artists, design and advertising agencies, primarily for special brochures and annual reports. These products also include base papers that are converted into finished products, such as envelopes, tablets, business forms and data processing/computer forms.

The Company also produces paper for several specialty and packaging markets. These products consist primarily of base stock for thermal printing, flexible packaging, food packaging, medical gowns and drapes, sandpapers backing, carbonless printing, labels and other coating a! nd lamina! ting applications. The Company also manufactures papers for industrial and specialty applications, including carrier papers, treated papers, security papers and specialized printing and converting applications. The Company sells business papers primarily to paper stationers, merchants, office equipment manufacturers and retail outlets. The Company distributes uncoated commercial printing and publishing papers to end-users and commercial printers, mainly through paper merchants, as well as selling directly to converters. The Company sells its specialty and packaging papers mainly to converters, who apply a further production process, such as coating, laminating, folding or waxing to its papers before selling them to a variety of specialized end-users.

Distribution

The Company's Distribution business involves the purchasing, warehousing, sale and distribution of the Company's various products and those of other manufacturers. These products include business, printing and publishing papers and certain packaging products. These products are sold to diverse customer base, which includes small, medium and large commercial printers, publishers, quick copy firms, catalog and retail companies and institutional entities. The Company's Distribution business operates in the United States and Canada under a single banner and umbrella name, Ariva. Ariva operates throughout the Northeast, Mid-Atlantic and Midwest areas from 16 locations in the United States, including 12 distribution centers serving customers across North America.

Personal Care

The Company's Personal Care business sells and manufactures adult incontinence products and distributes disposable washcloths marketed primarily under the Attends brand name. The Company is a supplier of adult incontinence products sold into North America and Northern Europe, selling to hospitals (acute cares) and nursing homes (long-term care) and the Company has a growing presence in the homecare and retail channels. The C! ompany op! erates two manufacturing facilities, with each having the ability to produce multiple product categories. The Company also has a research and development facility and production lines which manufacture high quality airlaid and ultrathin laminated absorbent cores.

Advisors' Opinion:

• [By Saibus Research]

  Weyerhaeuser is the largest forest products real estate investment trust in the United States. Weyerhaeuser grows and harvests trees, builds homes and makes a range of forest products essential to everyday lives. The company has undergone a dramatic level of strategic and organizational level change over the past several years in the wake of its debt-funded hostile takeover of Willamette Industries in 2002. In 2006, Weyerhaeuser agreed to spin off its fine paper business under a split-off transaction with Domtar (UFS). Under the terms of the deal, Weyerhaeuser would spin-off the fine paper business and the business would merge with Domtar Inc to create Domtar Corporation. Weyerhaeuser has four business segments as follows: